ESMO 2021, News
Adding Bevacizumab to Erlotinib Prolongs PFS in Non-Squamous Non-Small Cell Lung Cancer
There was no improvement in overall survival with bevacizumab.
Your search for non small cell lung cancer returned 4 results
ESMO 2021, News
Sugemalimab Deemed Effective as Consolidation for Stage III Non-Small Cell Lung Cancer
Sugemalimab improved progression-free survival whether patients received sequential or concurrent chemoradiotherapy.
ESMO 2021, News
Brigatinib Continues to Best Crizotinib in ALK+ Non-Small Cell Lung Cancer
There was an improvement in progression-free survival despite crossover.
ATS 2022
Predicting Lung Cancer: Risk-Based LDCT Screening vs Age and Pack-Years
Is lung cancer screening using risk-based low-dose computer tomography a better predictor of lung cancer risk than age or pack/years of smoking?
